$46.2m market cap
$0.42 last close
Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed vecabrutinib, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.
Investment summary
On 18 March, Sunesis released the first assessments of the 400mg cohort in its ongoing dosing study of vecabrutinib for B-cell malignancies. Two (of three) patients in this cohort showed stable disease (SD), with one showing a 48% response. These results are largely similar to those seen with the 300mg cohort (one near-responder SD, two stabilized SD, and one progressor). We would like to have seen more definitive activity in this cohort, but there is still the possibility that Sunesis will cross the line of generating partial responses (PRs) in the upcoming 500mg cohort.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 0.2 | (25.7) | (26.6) | (74.80) | N/A | N/A |
| 2019A | 2.1 | (23.3) | (23.3) | (26.78) | N/A | N/A |
| 2020E | 0.0 | (28.0) | (28.5) | (24.32) | N/A | N/A |
| 2021E | 0.0 | (32.7) | (35.7) | (29.22) | N/A | N/A |
Industry outlook
Sunesis is an oncology company with an early-stage asset with a validated target for the treatment of B-cell malignancies.
Last updated on 31/03/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 5.8 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| William Quinn | Chief Financial Officer and Senior Vice Presi |
